The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number:3235-0006
Expires:Oct 31, 2018
Estimated average burden
hours per response:23.8

COLUMN 1COLUMN 2COLUMN 3COLUMN 4COLUMN 5COLUMN 6COLUMN 7COLUMN 8
VALUESHRS ORSH/PUT/INVESTMENTOTHERVOTING AUTHORITY
NAME OF ISSUERTITLE OF CLASSCUSIP(x$1000)PRN AMTPRNCALLDISCRETIONMANAGERSOLESHAREDNONE
Clovis Oncology, Inc.Common Stock1894641001,514,584101,855SH OTR 0101,8550
CymaBay Therapeutics, Inc.Common Stock23257D1033,893,270543,753SH OTR 0543,7530
Gritstone Oncology, Inc.Common Stock39868T10534,566,6293,102,929SH OTR 03,102,9290
Second Sight Medical Products, Inc.Common Stock81362J1003,597,9744,492,975SH OTR 04,492,9750
Ocular Therapeutix, Inc.Common Stock67576A1009,747,6902,215,384SH OTR 02,215,3840
Audentes Therapeutics, Inc.Common Stock05070R10420,971,260553,916SH OTR 0553,9160
CRISPR Therapeutics AGCommon StockH17182108200,122,6254,248,888SH OTR 04,248,8880
OpGen, Inc.Common Stock68373L10940,121102,167SH OTR 0102,1670
Veracyte, Inc.Common Stock92337F10768,732,3362,410,815SH OTR 02,410,8150